Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SABBOBCATon Feb 17, 2023 9:05am
259 Views
Post# 35291708

Options

Options

The employee options that were set to expire in December have been extended and will now expire 10 days after the company is out of blackout. What will be very interesting to see is if post Earnings on Feb 28th will these exercise, expire, or remain in blackout? 

if they are exercised, then we know all the information was put on the table. Considering the low strike price, this is the most likely option. 

if they expire, this is worst case scenario as that would sow a complete lack of faith in the company. I would put this as highly unlikely.

Finally, if they remain in blackout and the expiry is extended, what material info isn't being shared? Could it be they need to wait until after the pause? Or could it be there is a deal in the works. Given that the research teams are working through the data and won't be submitting it to the SAC u til late March, I expect that it would be the latter regarding some sort of deal. 

Keep an eye out for SEDI filings in the first few weeks of March. They will be telling. 

<< Previous
Bullboard Posts
Next >>